Waiting for ODAC
This article was originally published in RPM Report
Executive SummaryInvestors in Amgen Inc. and Johnson & Johnson are staying on the sidelines until after a March 13 FDA advisory committee takes yet another look at the safety profile of the EPO brands Aranesp and Procrit. Here is a sampling of what analysts (and the two sponsors) are saying about the upcoming meeting.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
The innovator biopharma industry understandably concerned about a Trump Administration proposal to allow states to implement restrictive formularies while still collecting mandatory rebates. But the formulary protections in the Trump plan are an important message about the likely shape of any future changes to the US market.
Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.